Mohamad E. Sebai, MD General Practice Medicare: Medicare Enrolled Practice Location: 1410 N Washington Ave Apt 211, Royal Oak, MI 48067 Phone: 347-433-9498 |
News Archive
Transgene SA, a biopharmaceutical company that develops targeted immunotherapy products to treat major unmet medical needs in cancer and infectious diseases, today announced that favourable pre-clinical and clinical data on two Transgene products - TG1050 and TG4040 to treat chronic hepatitis B and chronic hepatitis C, respectively - will be presented in oral presentations at this year's European Association for the Study of the Liver Conference (Amsterdam, Netherlands, April 24-28, 2013).
Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for tofacitinib (development code CP-690,550), an investigational novel, oral JAK inhibitor being studied for the treatment of adult patients with moderately to severely active rheumatoid arthritis.
The Trust for America's Health applauds the U.S. Department of Health and Human Services for unveiling a new strategic approach to dealing with the silent epidemic of viral hepatitis today.
In a review article recently published in the journal Clinical and Translational Medicine, researchers from Boston University School of Medicine (BUSM) shed new light on the underlying processes of tumor metastasis and highlight the role of epigenetics in this process.
The 2010 AACP Interim Meeting, Patient-centered, Team-based Care: Setting the Standard, will provide attendees the opportunity to contemplate a healthcare system reorganized around the needs of patients and populations.
› Verified 7 days ago